BOOSTRIX-POLIO 2.5 LF / 0.5 ML
DIPHTHERIA TOXOID ADSORBED : 2.5 LF / 0.5 ML INACTIVATED POLIOVIRUS TYPE II : 8 D / 0.5 ML PERTACTIN ADSORBED : 2.5 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE III : 32 D / 0.5 ML PERTUSSIS TOXOID ADSORBED : 8 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE I : 40 D / 0.5 ML TETANUS TOXOID ADSORBED : 5.0 LF / 0.5 ML FILAMENTOUS HAEMAGGLUTININ ADSORBED : 8 MCG / 0.5 ML · DIN 02312557 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is BOOSTRIX-POLIO?
BOOSTRIX-POLIO 2.5 LF / 0.5 ML contains DIPHTHERIA TOXOID ADSORBED : 2.5 LF / 0.5 ML INACTIVATED POLIOVIRUS TYPE II : 8 D / 0.5 ML PERTACTIN ADSORBED : 2.5 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE III : 32 D / 0.5 ML PERTUSSIS TOXOID ADSORBED : 8 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE I : 40 D / 0.5 ML TETANUS TOXOID ADSORBED : 5.0 LF / 0.5 ML FILAMENTOUS HAEMAGGLUTININ ADSORBED : 8 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02312557, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 22-Oct-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BOOSTRIX-POLIO used for?
BOOSTRIX - POLIO (combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis) vaccine is indicated for: Booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. Passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see 4 DOSAGE AND ADMINISTRATION , 7 WARNINGS AND PRECAUTIONS , an d 14 CLINICAL TRIALS ) BOOSTRIX - POLIO is not intended for primary immunization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02312557 |
|---|---|
| Brand name | BOOSTRIX-POLIO |
| Generic / active ingredient | DIPHTHERIA TOXOID ADSORBED : 2.5 LF / 0.5 ML INACTIVATED POLIOVIRUS TYPE II : 8 D / 0.5 ML PERTACTIN ADSORBED : 2.5 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE III : 32 D / 0.5 ML PERTUSSIS TOXOID ADSORBED : 8 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE I : 40 D / 0.5 ML TETANUS TOXOID ADSORBED : 5.0 LF / 0.5 ML FILAMENTOUS HAEMAGGLUTININ ADSORBED : 8 MCG / 0.5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 2.5 LF / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07CA02 DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Oct-2010 |
| Original market date | 2010-10-22 00:00:00 |
How is it stored and handled?
null
How is it supplied?
0.5 mL pre-filled syringes in packages of 1 or 10
What can be used instead?
Other Canadian products sharing ATC code J07CA02 DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS. 4 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADACEL-POLIO | 29 UNIT / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02352044 |
| INFANRIX HEXA | 8 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | MARKETED | DIN 02253852 |
| QUADRACEL | 5 LF / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02534789 |
| DPT POLIO ADSORBED VACCINES | 25 LF / 0.5 ML | LIQUID | AVENTIS PASTEUR LIMITED | CANCELLED POST MARKET | DIN 00605050 |
| INFANRIX-IPV | 40 UNIT / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02241284 |
| QUADRACEL | 20 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02230946 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.